Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-escalation Clinical Study Evaluating the Safety of Camsirubicin With Prophylactic Pegfilgrastim in the Treatment of Advanced Soft Tissue Sarcomas

NCT05043649 is registered in ClinicalTrials.gov with Monopar Therapeutics as lead sponsor.

NCT NCT05043649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05043649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-escalation Clinical Study Evaluating the Safety of Camsirubicin With Prophylactic Pegfilgrastim in the Treatment of Advanced Soft Tissue Sarcomas
Lead sponsor
Monopar Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
September 22, 2021
Completion date
May 13, 2024
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft-tissue sarcoma